Cargando…
Infliximab in inflammatory bowel disease
Anti-tumor necrosis factor (TNF) therapy has revolutionized the medical treatment of the inflammatory bowel diseases (IBD), Crohn’s disease (CD), and ulcerative colitis. Twenty years ago, infliximab became the first anti-TNF agent approved for IBD. Data from randomized controlled trials, large obser...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6435871/ https://www.ncbi.nlm.nih.gov/pubmed/30937157 http://dx.doi.org/10.1177/2040622319838443 |
_version_ | 1783406721160445952 |
---|---|
author | Papamichael, Konstantinos Lin, Steve Moore, Matthew Papaioannou, Garyfallia Sattler, Lindsey Cheifetz, Adam S. |
author_facet | Papamichael, Konstantinos Lin, Steve Moore, Matthew Papaioannou, Garyfallia Sattler, Lindsey Cheifetz, Adam S. |
author_sort | Papamichael, Konstantinos |
collection | PubMed |
description | Anti-tumor necrosis factor (TNF) therapy has revolutionized the medical treatment of the inflammatory bowel diseases (IBD), Crohn’s disease (CD), and ulcerative colitis. Twenty years ago, infliximab became the first anti-TNF agent approved for IBD. Data from randomized controlled trials, large observational cohort studies, postmarketing registries, and meta-analyses show that infliximab is a very effective treatment for moderate to severe IBD with a good safety profile. Infliximab has been also used to treat pouchitis following an ileal pouch–anal anastomosis (IPAA) after restorative proctocolectomy and to prevent postoperative recurrence following an ileocolonic resection for CD with good results. Nevertheless, up to 30% of patients show no clinical benefit following induction and up to 50% lose response over time. Both these unwanted outcomes can be largely explained by inadequate drug concentrations and frequently by the development of antibodies to infliximab. Loss of response can be managed efficiently and often prevented by applying therapeutic drug monitoring. Recently, the first biosimilars of infliximab have been approved and are utilized in clinical practice with comparable efficacy and safety with the originator. This review will mainly focus on the efficacy of infliximab in IBD. |
format | Online Article Text |
id | pubmed-6435871 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-64358712019-04-01 Infliximab in inflammatory bowel disease Papamichael, Konstantinos Lin, Steve Moore, Matthew Papaioannou, Garyfallia Sattler, Lindsey Cheifetz, Adam S. Ther Adv Chronic Dis Review Anti-tumor necrosis factor (TNF) therapy has revolutionized the medical treatment of the inflammatory bowel diseases (IBD), Crohn’s disease (CD), and ulcerative colitis. Twenty years ago, infliximab became the first anti-TNF agent approved for IBD. Data from randomized controlled trials, large observational cohort studies, postmarketing registries, and meta-analyses show that infliximab is a very effective treatment for moderate to severe IBD with a good safety profile. Infliximab has been also used to treat pouchitis following an ileal pouch–anal anastomosis (IPAA) after restorative proctocolectomy and to prevent postoperative recurrence following an ileocolonic resection for CD with good results. Nevertheless, up to 30% of patients show no clinical benefit following induction and up to 50% lose response over time. Both these unwanted outcomes can be largely explained by inadequate drug concentrations and frequently by the development of antibodies to infliximab. Loss of response can be managed efficiently and often prevented by applying therapeutic drug monitoring. Recently, the first biosimilars of infliximab have been approved and are utilized in clinical practice with comparable efficacy and safety with the originator. This review will mainly focus on the efficacy of infliximab in IBD. SAGE Publications 2019-03-26 /pmc/articles/PMC6435871/ /pubmed/30937157 http://dx.doi.org/10.1177/2040622319838443 Text en © The Author(s), 2019 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Review Papamichael, Konstantinos Lin, Steve Moore, Matthew Papaioannou, Garyfallia Sattler, Lindsey Cheifetz, Adam S. Infliximab in inflammatory bowel disease |
title | Infliximab in inflammatory bowel disease |
title_full | Infliximab in inflammatory bowel disease |
title_fullStr | Infliximab in inflammatory bowel disease |
title_full_unstemmed | Infliximab in inflammatory bowel disease |
title_short | Infliximab in inflammatory bowel disease |
title_sort | infliximab in inflammatory bowel disease |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6435871/ https://www.ncbi.nlm.nih.gov/pubmed/30937157 http://dx.doi.org/10.1177/2040622319838443 |
work_keys_str_mv | AT papamichaelkonstantinos infliximabininflammatoryboweldisease AT linsteve infliximabininflammatoryboweldisease AT moorematthew infliximabininflammatoryboweldisease AT papaioannougaryfallia infliximabininflammatoryboweldisease AT sattlerlindsey infliximabininflammatoryboweldisease AT cheifetzadams infliximabininflammatoryboweldisease |